Yi-Long Wu

Yi-Long Wu

UNVERIFIED PROFILE

Are you Yi-Long Wu?   Register this Author

Register author
Yi-Long Wu

Yi-Long Wu

Publications by authors named "Yi-Long Wu"

Are you Yi-Long Wu?   Register this Author

100Publications

2817Reads

5Profile Views

Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives.

Cancer Lett 2019 Jun 12. Epub 2019 Jun 12.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.05.044DOI Listing
June 2019

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.

J Thorac Oncol 2019 May 17;14(5):924-932. Epub 2019 Jan 17.

Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.007DOI Listing
May 2019

Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis.

Future Oncol 2019 May 6;15(13):1481-1491. Epub 2019 Mar 6.

State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0944DOI Listing
May 2019

A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.

Lung Cancer 2019 May 18;131:134-138. Epub 2019 Mar 18.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.03.015DOI Listing
May 2019

The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer.

Lancet Oncol 2019 May 20. Epub 2019 May 20.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30148-2DOI Listing
May 2019

Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement.

J Thorac Oncol 2019 Apr 5;14(4):726-731. Epub 2018 Nov 5.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183341
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.10.161DOI Listing
April 2019

Application of indocyanine green fluorescence for precision sublobar resection.

Thorac Cancer 2019 Apr 7;10(4):624-630. Epub 2019 Feb 7.

Department of Thoracic Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.12972DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449268PMC
April 2019

Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.

J Thorac Oncol 2019 Apr;14(4):e81-e82

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China 510080. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.015DOI Listing
April 2019

Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network.

Oncologist 2019 Apr 17. Epub 2019 Apr 17.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0908DOI Listing
April 2019

Emerging therapies for non-small cell lung cancer.

J Hematol Oncol 2019 Apr 25;12(1):45. Epub 2019 Apr 25.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, People's Republic of China.

View Article

Download full-text PDF

Source
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-
Publisher Site
http://dx.doi.org/10.1186/s13045-019-0731-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482588PMC
April 2019

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Eur J Cancer 2019 Mar 7;109:183-191. Epub 2019 Feb 7.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou 510080, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.01.007DOI Listing
March 2019

The superstars of precision medicine-EGFR inhibitors in adjuvant treatment of lung cancer.

J Thorac Dis 2019 Jan;11(1):E11-E13

Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.12.72DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384350PMC
January 2019

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.

Lung Cancer 2018 12 1;126:133-138. Epub 2018 Nov 1.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.10.027DOI Listing
December 2018

Adjuvant TKIs: still an optimal choice.

J Thorac Dis 2018 Dec;10(12):E812-E814

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.11.67DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344745PMC
December 2018

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.

J Thorac Oncol 2018 11 26;13(11):1668-1675. Epub 2018 Jul 26.

Southern Medical University, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.07.016DOI Listing
November 2018

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 Nov 29;36(31):3101-3109. Epub 2018 Aug 29.

Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Li Zhang, Sun Yat-sen University Cancer Center, Guangdong; Xiaoqing Liu, Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing; Sylvia Zhao and Bin Peng, Novartis Institutes for Biomedical Research, Shanghai, People's Republic of China; Dong-Wan Kim, Seoul National University Hospital; Dae Ho Lee, University of Ulsan College of Medicine; Myung-Ju Ahn, Samsung Medical Center, Seoul, Republic of Korea; James Chih-Hsin Yang, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Johan F. Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Vincent Chia and Philippe Pultar, Novartis Pharmaceuticals, East Hanover, NJ; Sabine Glaser and Mikhail Akimov, Novartis Pharma AG, Basel, Switzerland; and Daniel S.W. Tan, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7326DOI Listing
November 2018

Prophylactic air-extraction strategy after thoracoscopic wedge resection.

Thorac Cancer 2018 11 6;9(11):1406-1412. Epub 2018 Sep 6.

The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.12850DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209782PMC
November 2018

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.

Lung Cancer 2018 11 14;125:86-92. Epub 2018 Sep 14.

School of Medicine, South China University of Technology, Guangzhou, 510006, China; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183056
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.09.010DOI Listing
November 2018

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

BMC Cancer 2018 Nov 26;18(1):1171. Epub 2018 Nov 26.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-5078-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258481PMC
November 2018

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 10 14;13(10):1539-1548. Epub 2018 Aug 14.

Department of Clinical Oncology, State Laboratory of South China, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.012DOI Listing
October 2018

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.

J Thorac Oncol 2018 09 30;13(9):1415-1421. Epub 2018 May 30.

Southern Medical University, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183063
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.05.024DOI Listing
September 2018

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.

Lancet Respir Med 2018 09 17;6(9):681-690. Epub 2018 Jul 17.

State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(18)30264-9DOI Listing
September 2018

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

J Clin Oncol 2018 Sep 30;36(26):2702-2709. Epub 2018 Jul 30.

Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Myung-Ju Ahn, Sungkyunkwan University School of Medicine; Hye Ryun Kim, Yonsei University College of Medicine, Seoul; Ji-Youn Han, National Cancer Center, Goyang, Republic of Korea; Marina Chiara Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Nobuyuki Katakami, Institute of Biomedical Research and Innovation, Kobe, Japan; Rachel Hodge, Paramjit Kaur, Andrew P. Brown, and Dana Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Vassiliki A. Papadimitrakopoulou, The University of Texas MD Anderson Cancer Center, Houston, TX; and Tony S.K. Mok, Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9363DOI Listing
September 2018

Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).

Lung Cancer 2018 09 18;123:7-13. Epub 2018 Jun 18.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, No. 106 Zhongshan 2nd Road, Guangzhou, Guangdong 510080, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.06.008DOI Listing
September 2018

Polycystic kidney and hepatic disease 1 gene mutations in von Meyenburg complexes: Case report.

World J Clin Cases 2018 Sep;6(9):296-300

Liver Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v6.i9.296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134282PMC
September 2018

Reply to L. Zeng et al.

J Clin Oncol 2018 Sep 13:JCO1800584. Epub 2018 Sep 13.

Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; and Koichi Goto, National Cancer Center Hospital East, Kashiwa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00584DOI Listing
September 2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 Aug 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4794DOI Listing
August 2018

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

J Clin Oncol 2018 Aug 4;36(22):2244-2250. Epub 2018 Jun 4.

Tony S. Mok, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Xiangdong Zhou, First Affiliated Hospital of Third Military Medical University, Chongqing; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; Ki Hyeong Lee, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea; Kazuhiko Nakagawa, Kindai University Hospital, Osaka; Seiji Niho, National Cancer Center Hospital East, Kashiwa, Japan; Min Lee, SFJ Asia Pacific, Singapore; Rolf Linke, SFJ Pharmaceuticals Group, Pleasanton, CA; Rafael Rosell, Catalan Institute of Oncology, Barcelona; Jesus Corral, Hospital Universitario Virgen del Rocio, Seville, Spain; Maria Rita Migliorino, Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy; Adam Pluzanski, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Eric I. Sbar, Pfizer, Collegeville, PA; Tao Wang and Jane Liang White, Pfizer, Groton, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7994DOI Listing
August 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

Toward innovative combinational immunotherapy: A systems biology perspective.

Cancer Treat Rev 2018 Jul 8;68:1-8. Epub 2018 May 8.

School of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, China; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372183006
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2018.05.003DOI Listing
July 2018

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.

Clin Lung Cancer 2018 07 1;19(4):e533-e536. Epub 2018 May 1.

Division of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183008
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.04.004DOI Listing
July 2018

Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in mutant patients with non-small cell lung cancer.

J Cancer 2018 30;9(17):2987-2993. Epub 2018 Jul 30.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.25679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134809PMC
July 2018

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

J Thorac Oncol 2018 06 23;13(6):792-800. Epub 2018 Mar 23.

Graduate Institute of Oncology, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.010DOI Listing
June 2018

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 May 29;36(14):1405-1411. Epub 2018 Mar 29.

Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Shun Lu, Jiao Tong University, Shanghai; Jianying Zhou, First Affiliated Hospital of Zhejiang University, Hangzhou, People's Republic of China; James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center, Seoul, South Korea; Takashi Seto, National Kyushu Cancer Center, Fukuoka; Noboru Yamamoto, National Cancer Center Hospital, Tokyo; Toshiaki Takahashi, Shizuoka Cancer Center, Shizuoka; Takeharu Yamanaka, Yokohama City University School of Medicine, Yokohama; Koichi Goto, National Cancer Center Hospital East, Kashiwa, Japan; Allison Kemner and Debasish Roychowdhury, OxOnc Development, Princeton, NJ; Nirvan Consultants, Lexington, MA; Jolanda Paolini and Tiziana Usari, Pfizer, Milan, Italy; and Keith D. Wilner, Pfizer, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5587DOI Listing
May 2018

Immunotherapy in the Asiatic population: any differences from Caucasian population?

J Thorac Dis 2018 May;10(Suppl 13):S1482-S1493

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.05.106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994501PMC
May 2018

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

J Thorac Oncol 2018 04 8;13(4):e49-e53. Epub 2017 Nov 8.

Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864173287
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2017.10.028DOI Listing
April 2018

Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

J Thorac Oncol 2018 04 18;13(4):521-532. Epub 2017 Dec 18.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.11.132DOI Listing
April 2018

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.

Cancer Immunol Immunother 2018 Mar 6;67(3):471-481. Epub 2017 Dec 6.

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhong-shan Er Road, Guangzhou, 510030, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2098-4DOI Listing
March 2018

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.

Lancet Oncol 2018 03;19(3):e127

Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30133-5DOI Listing
March 2018

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.

J Thorac Oncol 2018 01 7;13(1):85-96. Epub 2017 Nov 7.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.10.020DOI Listing
January 2018

Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.

Lung Cancer 2018 01 28;115:121-126. Epub 2017 Nov 28.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, PR China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.11.026DOI Listing
January 2018

Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.

Lancet Oncol 2018 01;19(1):e5

State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30924-5DOI Listing
January 2018

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

J Clin Oncol 2017 Dec 2;35(36):4027-4034. Epub 2017 Oct 2.

Tony S.K. Mok, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong, Special Administrative Region, People's Republic of China; Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Jie Wang, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing; You Lu, Sichuan University, Sichuan; Xiaojin Shi, AstraZeneca, Shanghai, People's Republic of China; James Chih-Hsin Yang, The National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China; Sang-We Kim, University of Ulsan College of Medicine; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kazuhiko Nakagawa, Kindai University; Shinji Atagi, Kinkichuo Chest Medical Center, Osaka, Japan; Santiago Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain; Yuri Rukazenkov, AstraZeneca, Cambridge; Vincent Haddad, AstraZeneca, Royston, United Kingdom; Kenneth S. Thress, AstraZeneca, Waltham, MA; and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9250DOI Listing
December 2017

Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

Cancer Treat Rev 2017 Dec 25;61:70-81. Epub 2017 Oct 25.

Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372173015
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2017.10.003DOI Listing
December 2017

Down-regulation of p16 and MGMT promotes the anti-proliferative and pro-apoptotic effects of 5-Aza-dC and radiation on cervical cancer cells.

Cell Biochem Funct 2017 Dec 15;35(8):488-496. Epub 2017 Nov 15.

Southern Medical University, Guangzhou, Guangdong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbf.3282DOI Listing
December 2017

Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.

Lung Cancer 2017 12 9;114:90-95. Epub 2017 Nov 9.

Medical Research Center, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.11.001DOI Listing
December 2017

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Lung Cancer 2017 12 7;114:96-102. Epub 2017 Nov 7.

Southern Medical University, Guangzhou, 510080, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, Guangzhou, 510080, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.11.005DOI Listing
December 2017

Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed.

J Thorac Dis 2017 Dec;9(12):4821-4824

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510515, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2017.10.152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757035PMC
December 2017

Molecular characteristics and clinical outcomes of exon 19 indel subtypes to EGFR TKIs in NSCLC patients.

Oncotarget 2017 Dec 30;8(67):111246-111257. Epub 2017 Nov 30.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762318PMC
December 2017

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.

J Thorac Oncol 2017 11 27;12(11):1723-1727. Epub 2017 Jun 27.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.06.017DOI Listing
November 2017

BRAIN study: it is hard to draw a conclusion - Authors' reply.

Lancet Respir Med 2017 11;5(11):e34

Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(17)30385-5DOI Listing
November 2017

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.

J Hematol Oncol 2017 10 23;10(1):167. Epub 2017 Oct 23.

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, Guangdong, 510080, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-017-0536-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654124PMC
October 2017

The changing landscape of clinical trial and approval processes in China.

Nat Rev Clin Oncol 2017 Sep 14;14(9):577-583. Epub 2017 Feb 14.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.10DOI Listing
September 2017

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.

J Thorac Oncol 2017 09 30;12(9):1368-1375. Epub 2017 May 30.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.05.018DOI Listing
September 2017

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells.

Clin Cancer Res 2017 Sep 12;23(18):5480-5488. Epub 2017 Jun 12.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0047DOI Listing
September 2017

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.

Cancer Lett 2017 09 19;403:186-194. Epub 2017 Jun 19.

Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2017.06.008DOI Listing
September 2017

The resistance mechanisms and treatment strategies for -mutant advanced non-small-cell lung cancer.

Oncotarget 2017 Sep 17;8(41):71358-71370. Epub 2017 Aug 17.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642641PMC
September 2017

Systemic tunnel dissection of mediastinal lymph nodes without clamping via uniportal video-assisted thoracoscopic surgery.

J Thorac Dis 2017 Sep;9(9):3272-3274

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2017.07.66DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708427PMC
September 2017

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review.

Authors:
Shan Su Yi-Long Wu

J Hematol Oncol 2017 08 7;10(1):147. Epub 2017 Aug 7.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-017-0514-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547513PMC
August 2017

Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value.

J Glob Oncol 2017 Aug 12;3(4):285-288. Epub 2016 Oct 12.

Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.2016.006734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560461PMC
August 2017

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.

J Hematol Oncol 2017 07 5;10(1):136. Epub 2017 Jul 5.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences and School of Medicine of South China University of Technology, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-017-0506-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499002PMC
July 2017

Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Clin Cancer Res 2017 Jun 30;23(12):3012-3024. Epub 2016 Dec 30.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2554DOI Listing
June 2017

Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer.

Chin Med J (Engl) 2017 Jun;130(12):1446-1453

Medical Research Center, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0366-6999.207478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463475PMC
June 2017

Osimertinib in EGFR T790M-Positive Lung Cancer.

N Engl J Med 2017 05;376(20):1993-4

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1703339DOI Listing
May 2017

Uniportal video-assisted thoracoscopic surgery left upper lobectomy and systematic lymph node dissection with fused fissure.

J Thorac Dis 2017 May;9(5):1375-1381

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

View Article

Download full-text PDF

Source
https://hub.hku.hk/bitstream/10722/226441/1/content.pdf?acce
Web Search
http://jtd.amegroups.com/article/view/13260/11340
Publisher Site
http://dx.doi.org/10.21037/jtd.2017.04.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465123PMC
May 2017

Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 04 6;35(11):1143-1145. Epub 2017 Mar 6.

Wen-Zhao Zhong, Si-Yang Liu, and Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.8544DOI Listing
April 2017

Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.

World J Surg Oncol 2017 Jan 9;15(1):12. Epub 2017 Jan 9.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12957-016-1064-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223594PMC
January 2017

Emerging challenges of advanced squamous cell lung cancer.

ESMO Open 2016 12;1(6):e000129. Epub 2016 Dec 12.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences , Guangzhou , China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174799PMC
December 2016

Misuse of Pirated Drugs: Why China? What Is Next?

J Glob Oncol 2016 Dec 22;2(6):440-441. Epub 2016 Jun 22.

Guangdong General Hospital and Guangdong Academy of Medical Science, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.2016.005348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493251PMC
December 2016